Novel Treatments to prevent and treat hearing loss

In the US, 50 million are affected with hearing loss or tinnitus. Unfortunately, there are no FDA approved drugs that treat a single disease or disorder of the inner ear. We are developing the first therapeutics that will prevent and treat sensorineural hearing loss and tinnitus.

Novel treatments to prevent and treat hearing loss

In the US, 50 million are affected with hearing loss or tinnitus. Unfortunately, there are no FDA approved drugs that treat a single disease or disorder of the inner ear. We are developing the first therapeutics that will prevent and treat sensorineural hearing loss and tinnitus.

  Overview

Sound Pharmaceuticals (SPI) is a privately held biopharmaceutical company in Seattle, WA.

Sound Pharmaceuticals, Inc. (SPI) is developing therapeutics that will enable doctors and patients to prevent and treat various forms of hearing loss. Sensorineural hearing loss is the third largest disease in the industrialized world and affects 50 million Americans. Estimates from the NIH and the CDC place the total annual costs of hearing loss at approximately $50 billion per year in the U.S. alone.

LEARN MORE

 Recent News

Sound Pharmaceuticals’ NIH Grant for a novel oral COVID-19 treatment increases to $4.2M

By News Short

Sound Pharmaceuticals, Inc. (SPI) is pleased to announce that is has received a $1.1M supplement to its $3.1M National Center for Advancing Translational Sciences (NCATS) Award, bringing the total NIH funding to $4.2M. SPI is developing ebselen (SPI-1005), a new molecular entity with anti-viral and anti-inflammatory activity, and enrolling two Phase 2 clinical trials for the treatment of hospitalized COVID-19 patients.
Read More

Otoprotection

Oral treatments for acute and chronic hearing loss

LEARN MORE

Chemoprotection

Oral combination for the treatment of acute ototoxicity

LEARN MORE

Regeneration

Locally delivered treatments for hearing restoration

LEARN MORE